Literature DB >> 17684291

Potential etiologic agents in sarcoidosis.

David R Moller1.   

Abstract

The etiology of sarcoidosis remains uncertain. The hallmark of sarcoidosis is the epithelioid granuloma, which serves as a necessary starting point for considering disease etiology. Any etiologic agent of sarcoidosis must also explain the typical clinical behaviors and characteristic immunopathologic features of the disease. One clinical observation that serves as a bridge to the etiology of sarcoidosis is the Kveim reaction. In this reaction, local epithelioid granulomas develop several weeks after the intradermal injection of homogenates of sarcoidosis tissue. Our group capitalized on the known properties of the Kveim reagent to search for candidate pathogenic tissue antigens in sarcoidosis without other a priori hypotheses regarding possible microbial or autoimmune etiologies. Using a limited proteomics approach based on the physicochemical properties of Kveim reagent, we detected a limited number of poorly soluble antigenic proteins in sarcoidosis tissues by protein immunoblotting, using sarcoidosis sera. Matrix-associated laser desorption/ionization-time of flight mass spectrometry identified one of these antigens to be the Mycobacterium tuberculosis catalase-peroxidase protein (mKatG). We found IgG responses to recombinant mKatG in more than 50% of patients with sarcoidosis but rarely in purified protein derivative (PPD)-negative control subjects. These findings support the conclusion that mKatG is a tissue antigen and target of the adaptive immune response in sarcoidosis, providing further evidence of a mycobacterial etiology in a subset of sarcoidosis. More generally, the approach used in these studies might be employed to discover and validate other candidate pathogenic antigens in sarcoidosis or other granulomatous disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17684291      PMCID: PMC2647598          DOI: 10.1513/pats.200608-155MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  17 in total

1.  The Kveim test in sarcoidosis. A study of 750 patients.

Authors:  L E SILTZBACH
Journal:  JAMA       Date:  1961-11-04       Impact factor: 56.272

2.  A case control etiologic study of sarcoidosis: environmental and occupational risk factors.

Authors:  Lee S Newman; Cecile S Rose; Eddy A Bresnitz; Milton D Rossman; Juliana Barnard; Margaret Frederick; Michael L Terrin; Steven E Weinberger; David R Moller; Geoffrey McLennan; Gary Hunninghake; Louis DePalo; Robert P Baughman; Michael C Iannuzzi; Marc A Judson; Genell L Knatterud; Bruce W Thompson; Alvin S Teirstein; Henry Yeager; Carol J Johns; David L Rabin; Benjamin A Rybicki; Reuben Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2004-09-03       Impact factor: 21.405

3.  Chemical inactivation of the Kveim reagent.

Authors:  D J Lyons; S Donald; D N Mitchell; G L Asherson
Journal:  Respiration       Date:  1992       Impact factor: 3.580

Review 4.  Th1 and Th2 responses regulate experimental lung granuloma development.

Authors:  S L Kunkel; N W Lukacs; R M Strieter; S W Chensue
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1996-09       Impact factor: 0.670

Review 5.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

6.  Familial sarcoidosis is linked to the major histocompatibility complex region.

Authors:  M Schürmann; P A Lympany; P Reichel; B Müller-Myhsok; K Wurm; M Schlaak; J Müller-Quernheim; R M du Bois; E Schwinger
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

7.  Selection of oligoclonal V beta-specific T cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis.

Authors:  J T Klein; T D Horn; J D Forman; R F Silver; A S Teirstein; D R Moller
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

Review 8.  Sarcoidosis: immunopathogenetic concepts and their clinical application.

Authors:  J Müller-Quernheim
Journal:  Eur Respir J       Date:  1998-09       Impact factor: 16.671

Review 9.  The role of mycobacteria in the pathogenesis of sarcoidosis.

Authors:  A J Hance
Journal:  Semin Respir Infect       Date:  1998-09

10.  Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis.

Authors:  Zhimin Song; Lisa Marzilli; Brian M Greenlee; Edward S Chen; Richard F Silver; Frederic B Askin; Alvin S Teirstein; Ying Zhang; Robert J Cotter; David R Moller
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  20 in total

Review 1.  Sarcoidosis and its otolaryngological implications.

Authors:  Katarzyna Mrówka-Kata; Dariusz Kata; Dariusz Lange; Grzegorz Namysłowski; Eugeniusz Czecior; Katarzyna Banert
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-09       Impact factor: 2.503

Review 2.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

3.  Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis.

Authors:  Nam-Sihk Lee; Laura Barber; Ali Kanchwala; Carter J H Childs; Yash P Kataria; Marc A Judson; Mark A Mazer; Sergio Arce
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

4.  M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.

Authors:  Stefan Prokop; Frank L Heppner; Hans H Goebel; Werner Stenzel
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.

Authors:  Karen C Patterson; Kyle Hogarth; Aliya N Husain; Anne I Sperling; Timothy B Niewold
Journal:  Transl Res       Date:  2012-04-10       Impact factor: 7.012

Review 6.  The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis.

Authors:  Antje Prasse
Journal:  Dtsch Arztebl Int       Date:  2016-08-22       Impact factor: 5.594

Review 7.  Interstitial lung diseases in children.

Authors:  Annick Clement; Nadia Nathan; Ralph Epaud; Brigitte Fauroux; Harriet Corvol
Journal:  Orphanet J Rare Dis       Date:  2010-08-20       Impact factor: 4.123

8.  ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.

Authors:  Andriy O Samokhin; Frank Bühling; Franz Theissig; Dieter Brömme
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

Review 9.  Dendritic cells in the pathogenesis of sarcoidosis.

Authors:  Lisa C Zaba; Gideon P Smith; Miguel Sanchez; Stephen D Prystowsky
Journal:  Am J Respir Cell Mol Biol       Date:  2009-04-16       Impact factor: 6.914

10.  [Granulomatous lung and systemic diseases].

Authors:  A Prasse; G Kayser; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.